(Q52937079)

9 May 2018

title

Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. (English)

1 reference

9 May 2018

main subject

acute myeloid leukemia

1 reference

Kardos G

1

1 reference

9 May 2018

Zwaan CM

2

1 reference

9 May 2018

Kaspers GJ

3

1 reference

9 May 2018

de-Graaf SS

4

1 reference

9 May 2018

de Bont ES

5

1 reference

9 May 2018

Postma A

6

1 reference

9 May 2018

Bökkerink JP

7

1 reference

9 May 2018

Weening RS

8

1 reference

9 May 2018

van der Does-van den Berg A

9

1 reference

9 May 2018

van Wering ER

10

1 reference

9 May 2018

Korbijn C

11

1 reference

9 May 2018

Hählen K

12

1 reference

9 May 2018

publication date

1 December 2005

1 reference

9 May 2018

published in

Leukemia

1 reference

9 May 2018

volume

19

1 reference

9 May 2018

issue

12

1 reference

9 May 2018

page(s)

2063-2071

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403873

exact match

0 references

cites work

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

[Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a European view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

New targets for therapy in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Treatment of acute myelogenous leukemia in children and adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Late effects of treatment in survivors of childhood acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403873

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403873

1 reference

9 May 2018

1 reference

9 May 2018